Paul J Gaglio, MD
Expertise:
About:
Paul J. Gaglio, MD FACP, AGAF, FAASLD, Professor of Medicine (in Surgery) is the director of Hepatology Outreach at NY-Presbyterian Hospital, Columbia University Irving Medical Center. He is the former medical director of Adult Liver Transplantation at The Montefiore Medical Center, Columbia Presbyterian Hospital, and The Tulane University Medical Center. Dr. Gaglio received his bachelor’s in Biology/Physiology from Rutgers College in New Brunswick, NJ, and his M.D. from UMDNJ-New Jersey Medical School. He completed an internship and residency at Mount Sinai Medical Center in New York City, and a digestive disease/liver transplantation fellowship at New Jersey Medical School. Dr. Gaglio has published multiple manuscripts, book chapters, and abstracts, and has participated in numerous research trials related to the therapy of hepatitis B and C, fatty liver disease, liver transplantation, and treatment of liver failure. Dr. Gaglio has lectured nationally and internationally on these topics. He is a Fellow of the American College of Physicians, the American Gastroenterological Association, and the American Association for the Study of Liver Diseases. His research interests include treatment of hepatitis B and C, the natural history of hepatitis C in liver transplant recipients, and non-alcoholic fatty liver disease. He is consistently listed in Castle Connolly Top Doctors; NY Metro Area, Marquis Who’s Who in America, and has received several teaching awards. In 2011, he was named Physician of the Year, NY Chapter of the American Liver Foundation.
Visit The Center for Liver Disease and Transplantation at columbiasurgery.org/liver
Honors:
2022 American Registry "Top Doctors"
2021-2022 NJ Monthly Top Doctors
2009-2022 "Best Doctors® in America"
2012-2022 Castle Connolly Top Doctors; New York Metro Area 2012-2022
2013-2022 Marquis Who's Who In America 2013-2022
2014 Fellow American Association for the Study of Liver Disease
2011 Physician of the Year, New York Chapter, American Liver Foundation
2008 Fellow American Gastroenterological Association
2001 Fellow American College of Physicians
2001 Surgical Housetaff Teaching Award Tulane University
Publications:
Thompson J, Jones N, Al-Khafaji A, Gaglio P, et al VTI-208 Study Group.Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis - A Multinational, Prospective, Controlled, Randomized Trial. Liver Transplantation 2018;24:380-393
Lubetzky, M, Soowan C, Joelson A, Coco M, Kamal L, Ajaimy M, Gaglio PJ, Akalin E and Deboccardo G Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents Transplantation. 2017;101(7):1704-1710
Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF. Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy. J Clin Exp Hepatol. 2016;6(2):100-8
Zahiruddin A, Farahmand A, Gaglio P, Massoumi H.Clinical characteristics and response to therapy of autoimmune hepatitis in an urban Latino population. Gastroenterol Hepatol Bed Bench. 2016;9(3):225-30.
Jermyn R, Soe E, D'Alessandro D, S
hin J, Jakobleff W, Schwartz D, Kinkhabwala M, Gaglio PJ. Cardiac failure after liver transplantation requiring a biventricular assist device. Case Rep Transplant. 2014;2014:946961
Tandan S, Sun K, Gaglio PJ A Rare Finding on Liver Explant. Clin Gastroenterol Hepatol. 2014 Sep;12(9):e85
Bichoupan K, Schwartz JM, Martert V, Giannattasio ER, Marfo K, Odin J, Liu L, Schiano T, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich D, Branch A, Reinus JP. Effect of Fibrosis on Adverse Events in Hepatitis C Patients treated with Telaprevir Aliment Pharmacol Ther. 2014;39:209-216.
Kinkhabwala M, Lindower J, Principe AL, Reinus J, Gaglio PJ. Expedited Liver Allocation in the US: A Critical Analysis. Liver Transplantation 2013;19(10):1159-65Gaglio PJ, Marfo K, Chiodo J. Hyponatremia in Cirrhosis and End Stage Liver Disease; Treatment with the Vasopressin V2 Receptor Antagonist Tolvaptan: Dig Dis Sci. 2012 Nov;57(11):2774-8
Flattau, A, Gaglio PJ, et al. Social Bariers to Adult Liver Transplantation Listing; Prevalence and Association with Program Characteristics: Liver Transpl. 2011;17:1167-1175
Degertekin B, Han SH, Keeffe EB, Gaglio PJ. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation.; NIH HBV-OLT Study Group. Am J Transplant. 2011;10:1823-33
Gaglio PJ, Moss N, McGaw C, Reinus J Direct Acting Antiviral Therapy for Hepatitis C; Attitudes Regarding Future Use: Dig Dis Sci. 2011;56:1509-15.